Researchers Create Human-like Antibody for Treatment of Alzheimer’s, PSP

Researchers Create Human-like Antibody for Treatment of Alzheimer’s, PSP
Tau bio-logic and LifeArc researchers have generated a human-like antibody called TBL-100 for the treatment of Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). An antibody is a large Y-shaped protein that’s naturally produced in response to invading foreign particles (antigens) such as viruses. A humanized antibody refers to an antibody that was generated in non-human species (commonly rodent) and whose protein sequence has been altered to increase its resemblance to naturally occurring human antibodies. By humanizing antibodies, scientists are making them less prone to trigger an unwanted immune response. Abnormal forms of the tau protein are known to have a tendency to aggregate and contribute to neurodegeneration. Importantly, toxic tau clumps have been found in both Alzheimer’s disease and progressive supranuclear palsy. The latter is a neurodegenerative disorder that causes impairment of balance and walking, impaired eye movement, abnormal muscle tone, speech difficulties, and problems swallowing and eating. TBL-100 targets the less abundant but highly toxic abnormally short fragments of tau (tauC3). This short protein fragment, although less abundant than full-length tau, exerts disproportionately large pathological effects. Evidence indicates that tauC3 occurs in the early stages of Alzheimer’s and that its levels correlate with cognitive impairment. Using brain tissue from Alzheimer’s patie
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *